IDH1 and central nervous system cancer: We identified 208 patients from the Cancer Genome Atlas Pan-Cancer Atlas with newly diagnosed primary IDH wild type gliomas (so-called “molecular GBMs”) whose samples had passed the Pan-Cancer quality assurance, the vast majority of whom received RT45.